Chapter 8 HPV vaccines

Frazer, Ian H. (2006) Chapter 8 HPV vaccines. International Journal of Gynecology and Obstetrics, 94 Supp. 1: S81-S88. doi:10.1016/S0020-7292(07)60014-9


Author Frazer, Ian H.
Title Chapter 8 HPV vaccines
Journal name International Journal of Gynecology and Obstetrics   Check publisher's open access policy
ISSN 0020-7292
1879-3479
Publication date 2006-11
Sub-type Article (original research)
DOI 10.1016/S0020-7292(07)60014-9
Volume 94
Issue Supp. 1
Start page S81
End page S88
Total pages 8
Editor Lynette Denny
Hextan Y. S. Ngan
Place of publication Shannon, Clare Ireland
Publisher Elsevier Ireland
Collection year 2006
Language eng
Subject 321010 Infectious Diseases
730115 Urogenital system and disorders
Abstract Vaccines to prevent infection with high-risk human papillomaviruses (HPV) will help protect women against cervical cancer, and some are likely to be available within the next year. One vaccine, a quadrivalent vaccine against HPV types 6, 11, 16 and 18 and known as Garadsil ©(Merck &Co., Inc), was approved by the Federal Drug Administration (FDA) for the prevention of cervical cancer, cervical cancer precursors and vulval and vaginal cancer precursors associated with HPV 16 and 18 in June 2006. In addition, the vaccine has been approved for the prevention of genital warts and low grade cervical lesions e.g. cervical intraepithelial neoplasia1. The main vaccines components are recombinant viral capsid proteins assembled into virus-like particles and alum-based adjuvants. If given before HPV infection, the vaccines, which induce HPV type-specific, virus-neutralizing antibodies, have proven safe and highly effective at preventing HPV infection and its clinical consequences, including high-grade cervical lesions. Their use should not immediately alter existing screening programs for cervical cancer, however. Because they incorporate only the 2 HPV types most commonly associated with cervical cancer (HPV-16 and HPV-18), they can only prevent about 70% of cervical cancers. Vaccines to treat existing HPV infection are under development but are unlikely to become clinically available in the near future.
Keyword Cervical cancer
Vaccination
Human papillomavirus
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown
Additional Notes Issue Title: Prevention and Treatment of HPV Associated Disease in the HPV Vaccine Era

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 4 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 10:09:47 EST